Designation of Pasireotide (as Embonate) (Signifor Lar) as an orphan drug - Novartis Pharmaceuticals

Overview

The Therapeutic Goods Act 1989 was enacted to provide a comprehensive framework for regulating therapeutic goods in Australia, ensuring their quality, safety, and efficacy. This legislation was introduced to address the need for a robust system that could manage the approval, registration, and monitoring of therapeutic products within the country. Enacted by the Australian Parliament, the Act aims to protect public health by controlling the supply and use of therapeutic goods, thereby safeguarding consumers from potential harm associated with substandard or improperly regulated products. The designation of Pasireotide (as Embonate) (SIGNIFOR LAR) as an orphan drug under the Act exemplifies the policy objective to encourage the development and availability of treatments for rare diseases, in this case, Acromegaly, by offering specific incentives to pharmaceutical companies.

Scope and Application

The Therapeutic Goods Act 1989, as amended, designates specific therapeutic goods and governs their regulation in Australia. In this particular instance, Pasireotide (known as SIGNIFOR LAR and marketed as EMBONATE) has been designated as an orphan drug for the treatment of acromegaly in patients for whom medical therapy is appropriate. This designation is pivotal for the development and availability of treatments for rare conditions, ensuring that drugs which might not otherwise be economically viable to develop are brought to market. The designation is made by a delegate of the Secretary under the authority conferred by the Therapeutic Goods Regulations 1990. The legislation thereby targets a specific pharmaceutical product, Pasireotide, administered in a modified release injection form, for a particular medical condition, and identifies Novartis Pharmaceuticals Australia Pty Ltd as the sponsor responsible for the therapeutic good. This application of the Act underscores its role in fostering innovation and access to treatments for rare diseases within the Australian healthcare system.

Key Provisions

The main operative sections of this legislation, as provided in the Gazette, involve the designation of Pasireotide (as Embonate) (SIGNIFOR LAR) as an orphan drug for the treatment of acromegaly, under section 16J of the Therapeutic Goods Regulations 1990 (paragraph 16J(2)). This designation is effective from 29 October 2013 and is made by Dr Anthony Gill, who is acting as the Delegate of the Secretary for the purposes of the Therapeutic Goods Act 1989. The specific therapeutic use for which Pasireotide (SIGNIFOR LAR) has been designated as an orphan drug is for patients with acromegaly for whom medical therapy is appropriate. The form of the drug in this context is a modified release injection. The sponsor of the drug, Novartis Pharmaceuticals Australia Pty Ltd, is also identified in the document. The obligations and requirements imposed by this Act on the parties or entities it governs are primarily related to the designation of Pasireotide (SIGNIFOR LAR) as an orphan drug. This designation can offer various benefits to the sponsor, including potential market exclusivity and financial incentives to encourage the development of treatments for rare diseases. The sponsor, in this case, Novartis Pharmaceuticals Australia Pty Ltd, must ensure that the drug is manufactured and marketed in compliance with all applicable regulations and standards set forth in the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. This includes adherence to good manufacturing practice (GMP) standards, as well as ensuring that the drug is safe, of high quality, and effective for its intended use. The legislation does not explicitly state any specific offences, penalties, or civil/criminal consequences for breach in the context of the orphan drug designation. However, any failure by the sponsor to comply with the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 could result in enforcement actions by the Therapeutic Goods Administration (TGA). Such actions may include product recalls, fines, and potential legal proceedings. The Therapeutic Goods Act 1989 provides for a wide range of penalties for breaches, which can vary depending on the nature and seriousness of the offence. These penalties can include substantial fines for individuals and corporations, as well as imprisonment in cases of serious or repeated breaches. The Therapeutic Goods Regulations 1990 may also provide for specific penalties related to the manufacture, supply, and advertising of therapeutic goods, which the sponsor must adhere to.